

Hematology & Oncology Center

12.21 1 2 - 2 - 2 - 2 C

Dockets Management Branch Food and Drug Administration Room 1-23 12420 Parklawn Drive Rockville MD 20857

April 2, 2003

RE: Docket # 02P-0435 (Citizen Petition)

Dear Sirs,

As a physician treating children with hemophilia and von Willebrand disease, I am requesting on behalf of my patients your agency's approval of Alphanate in the management of von Willebrand disease. The studies that other physicians have participated in have proven the efficacy of this product.

The pending approval of Alphanate for the treatment of von Willebrand disease will provide my patients an important supply option in case of shortages. Having another product that is approved for treatment of these patients may also help keep costs from escalating and be able to give patients options for their treatment.

Please consider the gravity and seriousness of this request and approve Alphanate's use in the management of von Willebrand disease.

Sincerely,

Joann M. Sanders MD

Bleeding Disorder Director

02 P-0435

C 14